Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 4—April 2011


High Rates of Staphylococcus aureus USA400 Infection, Northern Canada

George R. Golding, Paul N. Levett, Ryan R. McDonald, James Irvine, Brian Quinn, Mandiangu Nsungu, Shirley Woods, Mohammad Khan, Marianna Ofner-Agostini, Michael R. MulveyComments to Author , and the Northern Antibiotic Resistance Partnership
Author affiliations: Author affiliations: National Microbiology Laboratory, Winnipeg, Manitoba, Canada (G.R. Golding, M.R. Mulvey); Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada (P.N. Levett, R.R. McDonald); Population Health Unit, LaRonge, Saskatchewan (J. Irvine, B. Quinn); Northern Intertribal Health Authority, Prince Albert, Saskatchewan (M. Nsungu, S. Woods); Kelsey Trail Health Region, Melfort, Saskatchewan (M. Khan); Public Health Agency Canada, Ottawa, Ontario, Canada (M. Ofner-Agostini); University of Manitoba, Winnipeg, Manitoba (M.R. Mulvey)

Main Article

Table 2

Relationship of molecularly characterized MSSA isolates to MRSA epidemic strain types*

MRSA PFGE epidemic types (MLST) No. (%) related MSSA isolates PVL positive Predominant spa type†
CMRSA1/USA600 (ST45) 38 (13.3) 0 t065 (n = 23)
CMRSA2/USA100/800 (ST5) 77 (26.9) 0 t311 (n = 46)
CMRSA4/USA200 (ST36) 30 (10.5) 0 t012 (n = 12)
CMRSA7/USA400 (ST1) 12 (4.2) 12 t128 (n = 8)
CMRSA10/USA300 (ST8) 3 (1.1) 2 t008 (n = 2)
USA700 (ST72) 1(0.4) 0 t148 (n = 1)
ST97 18 (6.3) 0 t2728 (n = 11)
USA1000 (ST59) 33 (11.5) 1 t163 (n = 27)
USA1100 (ST30) 1 (0.4) 0 t122 (n = 1)

*n = 286 MSSA isolates. MSSA, methicilin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; PVL, Panton-Valentine leukocidin; PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; ST, sequence type.

Main Article

1Members of the Northern Antibiotic Resistance Partnership are listed at the end of this article.